Literature DB >> 22552285

HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.

Satoshi Nishizawa1, Yoshihiko Hirohashi, Toshihiko Torigoe, Akari Takahashi, Yasuaki Tamura, Takashi Mori, Takayuki Kanaseki, Kenjiro Kamiguchi, Hiroko Asanuma, Rena Morita, Alice Sokolovskaya, Junichi Matsuzaki, Ren Yamada, Reona Fujii, Harm H Kampinga, Toru Kondo, Tadashi Hasegawa, Isao Hara, Noriyuki Sato.   

Abstract

Cancer stem-like cells (CSC) are a small population of cancer cells with superior tumor initiating, self-renewal, and differentiation properties. In this study, we show that the cancer-testis antigen and HSP40 family member DNAJB8 contributes to the CSC phenotype in renal cell carcinoma (RCC). DNAJB8 overexpression increased the percentage of side population (SP) cells representing CSCs in RCC cells, enhancing their tumor-initiating ability. Conversely, attenuation of DNAJB8 decreased SP cells and reduced tumor-initiating ability. The utility of DNAJB8 as an immunologic target was established in DNA vaccination experiments. Compared with immunization with the tumor-associated antigen survivin, which was expressed in both CSCs and non-CSCs in RCC, immunization with Dnajb8 expression plasmids yielded stronger antitumor effects. Together, our findings suggest that DNAJB8 plays a role in CSC maintenance and that it offers a candidate for CSC-targeting immunotherapy in RCC. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552285     DOI: 10.1158/0008-5472.CAN-11-3062

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

Review 1.  Chemotherapy targeting cancer stem cells.

Authors:  Haiguang Liu; Lin Lv; Kai Yang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.

Authors:  Bo Yin; Yu Zeng; Xiaosong Wang; Gang Liu; Mo Zhang; Yongsheng Song
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.

Authors:  Lin Wang; Paul Park; Frank La Marca; Khoi D Than; Chia-Ying Lin
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-28       Impact factor: 4.553

4.  Tumor-initiating cells contribute to radiation resistance in primary human renal clear cell carcinomas by activating the DNA damage checkpoint response.

Authors:  Bo Li; Yong-Ju Gao; Xin-Yu Wu; Jing Cui; Ye Long; Jun-Ling Xu; De-Gang Ding
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

5.  Heat shock proteins in cancer stem cell maintenance: A potential therapeutic target?

Authors:  Giacomo Lettini; Silvia Lepore; Fabiana Crispo; Lorenza Sisinni; Franca Esposito; Matteo Landriscina
Journal:  Histol Histopathol       Date:  2019-07-19       Impact factor: 2.303

Review 6.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

Review 7.  Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets.

Authors:  Jeanette R McConnell; Shelli R McAlpine
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

Review 8.  Peptide vaccines in cancer-old concept revisited.

Authors:  Takumi Kumai; Hiroya Kobayashi; Yasuaki Harabuchi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2016-12-09       Impact factor: 7.486

9.  MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells.

Authors:  Bo Yin; Yu Zeng; Gang Liu; Xiaotian Wang; Peng Wang; Yongsheng Song
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

Review 10.  Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy.

Authors:  Alexander Kabakov; Anna Yakimova; Olga Matchuk
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.